| 영문 | beta-blocker | 한글 | 베타차단제 |
|---|---|---|---|
| 설명 | 베타-수용체(1과 2에 관계없이)의 기능을 억제시키는 약물로 이 수용체가 매개하여 생기는 신체의 변화를 억제한다. Propranolol이 좋은 예이다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| TGFA | transforming growth factor alpha; triglyceride fatty acid |
|---|---|
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| LTF | lactotransferrin; lipotropic factor; lymphocyte-transforming factor |
| GRF | gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow... |
| TGF-beta 1 | Transforming growth factor beta type 1 |
|---|---|
| TGF-beta RII | Transforming growth factor beta type II receptor |
| TGF beta | Transforming growth factor type beta |
| TGF-beta 1 | Transforming growth factor type beta 1 |
| TGF-beta RII | transforming growth factor beta receptor type II |
| receptors, growth factor | Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells. (12 Dec 1998) |
|---|---|
| receptors, insulin-like-growth factor I | Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity. (12 Dec 1998) |
| receptors, insulin-like-growth-factor II | Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity. (12 Dec 1998) |
| receptors, nerve growth factor | Cell surface receptors that bind nerve growth factor (ngf) and trigger intracellular changes influencing the behaviour of cells. Nerve growth factor receptors mediate the effects of nerve growth factor on the survival and growth of neurons. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| growth factor | <biochemistry> A complex family of polypeptide hormones or biological factors that are produced by the body to control growth, division and maturation of blood cells by the bone marrow. They regulate the division and proliferation of cells and influence the growth rate of some cancers. These factors occur naturally but some can be synthesised using molecular biology techniques and are used clinically to stimulate normal white cell production following chemotherapy or bone marrow transplantation. Examples include epidermal growth factor, platelet-derived growth factor, fibroblast growth factor. Insulin and somatomedin are also growth factors, the status of nerve growth factor is more uncertain. Perturbation of growth factor production or of the response to growth factor is important in neoplastic transformation. (29 Sep 1997) |
| growth hormone-releasing factor | <endocrinology> Peptide hormone related to the glucagon family, released from the pituitary, acts on the adenohypophysis to release growth hormone. Synonym: somatoliberin, growth hormone-releasing factor. (20 Sep 2002) |
| platelet-derived growth factor | <growth factor> The major mitogen in serum for growth in culture of cells of connective tissue origin. It consists of 2 different but homologous polypeptides A and B (~30,000 D) linked by disulphide bonds. Believed to play a role in wound healing. It is carried in the alpha-granules of platelets and is released when platelets adhere to traumatised tissues. Connective tissue cells near the traumatised region respond by initiating the process of replication. The B chain is almost identical in sequence to p28sis, the transforming protein of simian sarcoma virus, that can transform only those cells that express receptors for platelet derived growth factor, suggesting that transformation is caused by autocrine stimulation. The receptor is a tyrosine kinase. Acronym: PDGF (12 Dec 1998) |
| sarcoma growth factor | <growth factor> Polypeptide released by sarcoma cells that promotes the growth of cells by binding to a cell surface receptor, the sarcoma cell is therefore self sufficient and independent of normal growth control. See: growth factors. The name is no longer commonly used. (18 Nov 1997) |
| heparin binding growth factor | <growth factor> Acidic fibroblast growth factor (alpha FGF, HBGF 1) and basic FGF (beta FGF, HBGF 2) are the two founder members of a family of structurally related growth factors for mesodermal or neuroectodermal cells. Synonym: heparin binding growth factor. Acronym: FGF (18 Nov 1997) |
| hepatocyte growth factor | <growth factor> Polypeptide mitogen originally shown to cause cell division in hepatocytes. In the liver, the main sources of hepatocyte growth factor are nonparenchymal cells. It is now clear that hepatocyte growth factor is a mitogen for a number of cell types and it is found in many cells outside the liver, including platelets. Hepatocyte growth factor is synthesised as a single chain precursor that is proteolytically cleaved to give a heavy chain (70 kD) and a light chain (30 kD) linked by a single disulphide bond. It contains multiple copies of the kringle domain. However, both the single chain precursor and the two chain forms of hepatocyte growth factor are biologically active and hepatocyte growth factor is generally isolated as a mixture of the two forms. Hepatocyte growth factor also alters cell motility and is now known to be identical to scatter factor. Acronym: HGF (18 Nov 1997) |
| schwannoma derived growth factor | <growth factor> A growth factor containing an EGF like domain, mitogenic for astrocytes, Schwann cells and fibroblasts. (18 Nov 1997) |
| nerve growth factor | <growth factor> A peptide (13.26 kD) of 118 amino acids (usually dimeric) with both chemotropic and chemotrophic properties for sympathetic and sensory neurons. Found in a variety of peripheral tissues, nerve growth factor attracts neurites to the tissues by chemotropism, where they form synapses. The successful neurons are then protected from neuronal death by continuing supplies of nerve growth factor. It is also found at exceptionally high levels in snake venom and male mouse submaxillary salivary glands, from which it is commercially extracted. Nerve growth factor was the first of a family of nerve tropic factors to be discovered. Amino acids 1-81 show homology with proinsulin. Besides its peripheral actions, nerve growth factor selectively enhances the growth of cholinergic neurons that project to the forebrain and that degenerate in Alzheimer's disease. Acronym: NGF (18 Nov 1997) |
| nerve growth factor antiserum | An antiserum containing antibodies against nerve growth factor; when injected into newborn animals the majority of sympathetic ganglion cells are permanently destroyed, resulting in hypoinnervation of peripheral tissues. Synonym: NGF antiserum. (05 Mar 2000) |
| insulin like growth factor | <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin. They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present). Insulin like growth factor I = somatomedin A = somatomedin C Insulin like growth factor II = MSA (Multiplication stimulating activity). Insulin like growth factor 1 is released from the liver in response to growth hormone. Acronym: IGF (18 Nov 1997) |